CL2012000263A1 - Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc. - Google Patents

Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc.

Info

Publication number
CL2012000263A1
CL2012000263A1 CL2012000263A CL2012000263A CL2012000263A1 CL 2012000263 A1 CL2012000263 A1 CL 2012000263A1 CL 2012000263 A CL2012000263 A CL 2012000263A CL 2012000263 A CL2012000263 A CL 2012000263A CL 2012000263 A1 CL2012000263 A1 CL 2012000263A1
Authority
CL
Chile
Prior art keywords
copd
useful
treatment
inflammatory diseases
compounds derived
Prior art date
Application number
CL2012000263A
Other languages
English (en)
Inventor
Lilian Alcaraz
Andrew Bailey
Nicholas Kindon
Original Assignee
Astrazeneca Ab
Pulmagen Therapeutics Synergy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41129405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012000263(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab, Pulmagen Therapeutics Synergy filed Critical Astrazeneca Ab
Publication of CL2012000263A1 publication Critical patent/CL2012000263A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Un compuesto o una sal farmacéiuticamente aceptable del mismo.
CL2012000263A 2009-07-31 2012-01-31 Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc. CL2012000263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0913342.2A GB0913342D0 (en) 2009-07-31 2009-07-31 Compounds - 801

Publications (1)

Publication Number Publication Date
CL2012000263A1 true CL2012000263A1 (es) 2012-08-31

Family

ID=41129405

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012000263A CL2012000263A1 (es) 2009-07-31 2012-01-31 Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc.

Country Status (34)

Country Link
US (2) US8455483B2 (es)
EP (1) EP2459572B1 (es)
JP (1) JP5612092B2 (es)
KR (1) KR101664525B1 (es)
CN (1) CN102625808B (es)
AR (1) AR080601A1 (es)
AU (1) AU2010277384B2 (es)
BR (1) BR112012008043A2 (es)
CA (1) CA2768527C (es)
CL (1) CL2012000263A1 (es)
CO (1) CO6491034A2 (es)
CR (1) CR20120054A (es)
CU (1) CU24103B1 (es)
DO (1) DOP2012000032A (es)
EA (1) EA020566B1 (es)
ES (1) ES2702467T3 (es)
GB (1) GB0913342D0 (es)
GT (1) GT201200028A (es)
HK (1) HK1171755A1 (es)
HN (1) HN2012000217A (es)
IL (1) IL217557A (es)
MX (1) MX2012001232A (es)
MY (1) MY163117A (es)
NI (1) NI201200018A (es)
NZ (1) NZ597589A (es)
PE (1) PE20121441A1 (es)
SA (1) SA110310628B1 (es)
SG (1) SG177634A1 (es)
TR (1) TR201819140T4 (es)
TW (1) TWI443103B (es)
UA (1) UA106887C2 (es)
UY (1) UY32814A (es)
WO (1) WO2011012896A2 (es)
ZA (1) ZA201201473B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA100400C2 (uk) 2008-02-06 2012-12-25 Астразенека Аб Похідні спіроциклічних амідів
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
TWI466885B (zh) 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
GB201021979D0 (en) * 2010-12-23 2011-02-02 Astrazeneca Ab New compound
GB201021992D0 (en) * 2010-12-23 2011-02-02 Astrazeneca Ab Compound
US10435375B2 (en) 2015-05-05 2019-10-08 Northwestern University CXCR4 chemokine receptor modulators
WO2018059537A1 (zh) * 2016-09-30 2018-04-05 四川海思科制药有限公司 一种二氮杂螺[5.5]十一碳烷衍生物及其用途
AU2017376363B2 (en) 2016-12-14 2020-02-06 Beijing Showby Pharmaceutical Co., Ltd. Class of bifunctional compounds with quaternary ammonium salt structure
CA3065309A1 (en) 2017-06-01 2018-12-06 Bristol-Myers Squibb Company Substituted nitrogen containing compounds
EP3682906A1 (en) * 2019-01-17 2020-07-22 Julius-Maximilians-Universität Würzburg Compound targeting norepinephrine transporter

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2707186A (en) 1954-05-06 1955-04-26 Hoffmann La Roche Imidazolone derivatives
AU565621B2 (en) 1983-04-26 1987-09-24 Smithkline Beckman Corporation Dopaminergic carbostyrils
FR2665440B1 (fr) 1990-07-31 1994-02-04 Lipha Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant.
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SK285141B6 (sk) 1996-02-13 2006-07-07 Astrazeneca Uk Limited Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
GB9604578D0 (en) 1996-03-04 1996-05-01 Sericol Ltd Photocurable compositions
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
CA2411160A1 (en) 2000-07-07 2002-01-17 Angiogene Pharmaceuticals Limited Colchinol derivatives as vascular damaging agents
JP4851937B2 (ja) * 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
US7504400B2 (en) 2004-03-10 2009-03-17 Janssen Pharmaceutica N.V. MTP inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
US20050215542A1 (en) 2004-03-23 2005-09-29 Pfizer Inc Compounds for the treatment of diseases
DE102004024453A1 (de) * 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
MX2007004480A (es) 2004-10-15 2007-05-08 Astrazeneca Ab Quinoxalinas como inhibidores b raf.
WO2006051373A1 (en) 2004-11-12 2006-05-18 Pfizer Limited Compounds for the treatment of diseases
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
WO2006088173A1 (ja) 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Ｈｉｖインテグラーゼ阻害活性を有する２環性カルバモイルピリドン誘導体
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
ES2407115T3 (es) * 2005-11-18 2013-06-11 Ono Pharmaceutical Co., Ltd. Compuesto que contiene un grupo básico y uso del mismo
TW200734342A (en) 2005-12-15 2007-09-16 Astrazeneca Ab New compounds for the treatment of cardiac arrhythmias
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
GB0613154D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP2051712A2 (en) * 2006-08-15 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
CA2672792A1 (en) * 2006-12-20 2008-06-26 Astrazeneca Ab Amine derivatives and their use in beta-2-adrenoreceptor mediated diseases
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
GB0702413D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
UA100400C2 (uk) * 2008-02-06 2012-12-25 Астразенека Аб Похідні спіроциклічних амідів
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801

Also Published As

Publication number Publication date
US8476265B2 (en) 2013-07-02
US8455483B2 (en) 2013-06-04
JP5612092B2 (ja) 2014-10-22
GB0913342D0 (en) 2009-09-16
MX2012001232A (es) 2012-03-26
MY163117A (en) 2017-08-15
UA106887C2 (uk) 2014-10-27
CA2768527C (en) 2017-07-11
EP2459572B1 (en) 2018-09-12
EA201290077A1 (ru) 2012-08-30
CU20120021A7 (es) 2012-06-21
DOP2012000032A (es) 2017-08-15
AU2010277384A1 (en) 2012-03-22
CA2768527A1 (en) 2011-02-03
NI201200018A (es) 2012-09-10
SG177634A1 (en) 2012-02-28
CR20120054A (es) 2012-03-26
CN102625808B (zh) 2014-08-27
KR101664525B1 (ko) 2016-10-11
TWI443103B (zh) 2014-07-01
TW201107335A (en) 2011-03-01
EA020566B1 (ru) 2014-12-30
NZ597589A (en) 2013-12-20
EP2459572A2 (en) 2012-06-06
WO2011012896A2 (en) 2011-02-03
ZA201201473B (en) 2012-11-28
HK1171755A1 (en) 2013-04-05
IL217557A0 (en) 2012-02-29
AR080601A1 (es) 2012-04-25
KR20120056838A (ko) 2012-06-04
CO6491034A2 (es) 2012-07-31
CN102625808A (zh) 2012-08-01
SA110310628B1 (ar) 2014-02-27
JP2013500958A (ja) 2013-01-10
UY32814A (es) 2011-02-28
ES2702467T3 (es) 2019-03-01
AU2010277384B2 (en) 2014-01-30
CU24103B1 (es) 2015-07-30
US20110053909A1 (en) 2011-03-03
BR112012008043A2 (pt) 2020-08-25
WO2011012896A3 (en) 2011-04-21
TR201819140T4 (tr) 2019-01-21
HN2012000217A (es) 2015-03-09
PE20121441A1 (es) 2012-11-16
GT201200028A (es) 2013-09-26
IL217557A (en) 2015-01-29
US20130018037A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
CL2012000263A1 (es) Compuestos derivados de amidas espiro ciclica, agonista b-adrenoreceptor y antagonista muscarinico; utiles en el tratamiento en enfermedades inflamatorias, tales como epoc.
ES2659758T3 (es) Antagonistas de receptores de 5-HT3
SMT201600040B (it) Rilascio non covalente peptide-mediato di agenti attivi attraverso la barriera emato-encefalica
JP2011168603A5 (es)
CL2015001231A1 (es) Compuestos heterocíclicos sustituidos con amida; composicion farmaceutica; útiles en el tratamiento de una enfermedad inflamatoria o autoinmune.
CR20120177A (es) Nuevos compuestos de espiropiperidina y el uso farmacéutico del mismo para el tratamiento de diabetes
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
CR20110343A (es) Inhibidores de proteína cinasa
CO6501183A2 (es) Piperidinas sustituidas como antagonistas de ccr3
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
AR088297A1 (es) R(+)-n-formil-propargil-aminoindano
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
GT201300241A (es) Composicion farmaceutica antihipertensiva
EA201370149A1 (ru) Антагонисты рецептора
UY35209A (es) Compuestos tricíclicos
UY35211A (es) Compuestos tricíclicos
SMT201600041B (it) Agenti terapeutici 713
IL229081A0 (en) Isazolines as therapeutic agents
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
ES2571452T3 (es) Compuesto antagonista de leucotrieno B4
ECSP13012653A (es) COMPUESTOS DE OXAZOL[5,4-b]PIRIDIN-5-ILO Y SU USO PARA EL TRATAMIENTO DE CÁNCER